Halozyme Therapeutic (HALO)

$59.99 +0.97 (1.64%)
Market Cap 7.27B
Revenue (ttm) 1.02B
Net Income (ttm) 444.09M
EPS (ttm) N/A
PE Ratio 14.14
Forward PE 11.62
Profit Margin 43.74%
Debt to Equity Ratio 3.13
Volume 1,110,400
Avg Vol 2,074,100
Day's Range N/A - N/A
Shares Out 123.22M
Stochastic %K 60%
Beta 1.17
Analysts Sell
Price Target $65.89

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 794 8889
Fax: 858 704 8311
Address:
12390 El Camino Real, San Diego, United States
Sean29md
Sean29md Aug. 2 at 9:15 PM
$HALO the 50 and 200 day moving averages for Halozyme will likely be crossing on Tuesday coinciding with the quarterly earnings call. Amazing!
0 · Reply
Following_the_trend
Following_the_trend Jul. 31 at 4:18 PM
$HALO Strong into E/R.
0 · Reply
Sean29md
Sean29md Jul. 31 at 1:04 PM
$HALO In the second quarter of 2025, Darzalex (daratumumab), including its subcutaneous formulation Darzalex Faspro, achieved worldwide net trade sales of USD 3,539 million, as reported by Johnson & Johnson (J&J). This figure includes USD 2,017 million in the U.S. and USD 1,521 million in the rest of the world. These sales exceeded analyst expectations, which were set at USD 3,380 million for the quarter. The strong performance of Darzalex, driven significantly by the subcutaneous Faspro formulation, contributed to J&J beating overall profit estimates for the quarter. Thus, Darzalex Faspro sales in Q2 2025 outperformed analyst expectations by approximately USD 159 million.
0 · Reply
Sean29md
Sean29md Jul. 31 at 12:59 PM
$HALO Argenx Q2 Vyvgart sale far exceeded expectations. Argx stock is up 15% today. https://argenx.com/content/dam/argenx-corp/media-documents/argenx_Half-Year_2025_Financial_Report.pdf
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 30 at 7:56 PM
$HALO Outstanding article that hits the mark on HALO's current state. So if you want to refresh your HALO insights or learn about HALO from scratch, this is a must read. https://beyondspx.com/article/halozyme-unlocking-blockbuster-potential-with-a-patented-delivery-engine-halo
0 · Reply
Doozio
Doozio Jul. 30 at 7:14 PM
Chop chop huckleberries may da $HALO project yo. 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Jul. 27 at 9:14 PM
$PTHS let’s finish that monthly bar there as they slap the $HALO back on it in RYTM.
0 · Reply
Sean29md
Sean29md Jul. 25 at 10:53 PM
$HALO https://www.tipranks.com/news/company-announcements/halozymes-promising-cancer-study-a-potential-game-changer-in-oncology
1 · Reply
Halo202
Halo202 Jul. 24 at 12:33 AM
$HALO $60 tomorrow
0 · Reply
Sean29md
Sean29md Jul. 23 at 4:21 PM
$HALO https://www.prnewswire.com/news-releases/european-commission-approved-darzalex-faspro-for-adult-patients-with-smouldering-multiple-myeloma-302512103.html
0 · Reply
Latest News on HALO
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Jul 23, 2025, 11:36 AM EDT - 12 days ago

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Jul 22, 2025, 8:30 AM EDT - 13 days ago

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)

Jul 14, 2025, 4:33 PM EDT - 21 days ago

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)

Halozyme Therapeutics Added to Russell 1000® Index

Jun 30, 2025, 4:05 PM EDT - 5 weeks ago

Halozyme Therapeutics Added to Russell 1000® Index

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Jun 20, 2025, 1:15 PM EDT - 6 weeks ago

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme to Participate at Upcoming Investor Conferences

May 28, 2025, 4:05 PM EDT - 2 months ago

Halozyme to Participate at Upcoming Investor Conferences

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 28, 2025, 8:30 AM EDT - 2 months ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 12, 2025, 10:44 AM EDT - 3 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:15 PM EDT - 3 months ago

Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

May 6, 2025, 4:01 PM EDT - 3 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

May 5, 2025, 5:15 PM EDT - 3 months ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

May 1, 2025, 9:06 AM EDT - 3 months ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

Halozyme to Report First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 8:30 AM EDT - 3 months ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 28, 2025, 7:30 AM EDT - 3 months ago

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Apr 24, 2025, 8:30 AM EDT - 3 months ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 10, 2025, 6:15 PM EDT - 4 months ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Apr 9, 2025, 8:45 AM EDT - 4 months ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Apr 7, 2025, 9:29 AM EDT - 4 months ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Mar 31, 2025, 8:30 AM EDT - 4 months ago

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Joins the $1 Billion Club

Mar 21, 2025, 7:35 AM EDT - 4 months ago

Halozyme Joins the $1 Billion Club

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 8:30 AM EST - 5 months ago

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 7:55 PM EST - 5 months ago

Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript

HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

Feb 18, 2025, 4:01 PM EST - 5 months ago

HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 4, 2025, 8:30 AM EST - 6 months ago

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Feb 3, 2025, 7:30 AM EST - 6 months ago

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

Jan 8, 2025, 7:00 AM EST - 7 months ago

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

Jan 6, 2025, 8:30 AM EST - 7 months ago

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025

Jan 3, 2025, 3:42 PM EST - 7 months ago

Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025

Halozyme: Recent Approvals Alter My Appetite

Dec 31, 2024, 2:41 AM EST - 7 months ago

Halozyme: Recent Approvals Alter My Appetite

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Dec 30, 2024, 7:00 AM EST - 7 months ago

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Dec 30, 2024, 6:45 AM EST - 7 months ago

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

Dec 30, 2024, 6:30 AM EST - 7 months ago

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

Halozyme to Present at Upcoming Investor Conferences

Nov 27, 2024, 8:30 AM EST - 8 months ago

Halozyme to Present at Upcoming Investor Conferences

Halozyme withdraws $2.1 bln buyout offer for Evotec

Nov 22, 2024, 8:55 AM EST - 9 months ago

Halozyme withdraws $2.1 bln buyout offer for Evotec

EVO

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

Nov 22, 2024, 8:35 AM EST - 9 months ago

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

EVO

Halozyme CEO: Evotec Is Poised for Growth

Nov 18, 2024, 4:00 PM EST - 9 months ago

Halozyme CEO: Evotec Is Poised for Growth

EVO

Halozyme says €2 billion takeover of Evotech would create leader in drug discovery

Nov 18, 2024, 7:49 AM EST - 9 months ago

Halozyme says €2 billion takeover of Evotech would create leader in drug discovery

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Nov 18, 2024, 7:00 AM EST - 9 months ago

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

EVO

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

Nov 15, 2024, 12:56 PM EST - 9 months ago

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

EVO

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

Nov 14, 2024, 4:15 PM EST - 9 months ago

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

EVO

Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports

Nov 14, 2024, 4:09 PM EST - 9 months ago

Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports

EVO

Halozyme: Looking For More Growth Following Record Q3 Earnings

Nov 5, 2024, 12:24 PM EST - 9 months ago

Halozyme: Looking For More Growth Following Record Q3 Earnings

Halozyme Announces Record Earnings, Guidance

Nov 1, 2024, 11:42 AM EDT - 9 months ago

Halozyme Announces Record Earnings, Guidance

Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 7:39 PM EDT - 9 months ago

Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Oct 31, 2024, 4:01 PM EDT - 9 months ago

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

Oct 24, 2024, 6:30 AM EDT - 10 months ago

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

Halozyme to Report Third Quarter 2024 Financial and Operating Results

Oct 23, 2024, 4:30 PM EDT - 10 months ago

Halozyme to Report Third Quarter 2024 Financial and Operating Results

Wells Fargo Downgrades Halozyme Therapeutics (HALO) Due to Limited Upside

Oct 8, 2024, 4:12 AM EDT - 10 months ago

Wells Fargo Downgrades Halozyme Therapeutics (HALO) Due to Limited Upside

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

Oct 3, 2024, 8:00 AM EDT - 10 months ago

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm

Sep 17, 2024, 8:00 AM EDT - 11 months ago

Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm

Sean29md
Sean29md Aug. 2 at 9:15 PM
$HALO the 50 and 200 day moving averages for Halozyme will likely be crossing on Tuesday coinciding with the quarterly earnings call. Amazing!
0 · Reply
Following_the_trend
Following_the_trend Jul. 31 at 4:18 PM
$HALO Strong into E/R.
0 · Reply
Sean29md
Sean29md Jul. 31 at 1:04 PM
$HALO In the second quarter of 2025, Darzalex (daratumumab), including its subcutaneous formulation Darzalex Faspro, achieved worldwide net trade sales of USD 3,539 million, as reported by Johnson & Johnson (J&J). This figure includes USD 2,017 million in the U.S. and USD 1,521 million in the rest of the world. These sales exceeded analyst expectations, which were set at USD 3,380 million for the quarter. The strong performance of Darzalex, driven significantly by the subcutaneous Faspro formulation, contributed to J&J beating overall profit estimates for the quarter. Thus, Darzalex Faspro sales in Q2 2025 outperformed analyst expectations by approximately USD 159 million.
0 · Reply
Sean29md
Sean29md Jul. 31 at 12:59 PM
$HALO Argenx Q2 Vyvgart sale far exceeded expectations. Argx stock is up 15% today. https://argenx.com/content/dam/argenx-corp/media-documents/argenx_Half-Year_2025_Financial_Report.pdf
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 30 at 7:56 PM
$HALO Outstanding article that hits the mark on HALO's current state. So if you want to refresh your HALO insights or learn about HALO from scratch, this is a must read. https://beyondspx.com/article/halozyme-unlocking-blockbuster-potential-with-a-patented-delivery-engine-halo
0 · Reply
Doozio
Doozio Jul. 30 at 7:14 PM
Chop chop huckleberries may da $HALO project yo. 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Jul. 27 at 9:14 PM
$PTHS let’s finish that monthly bar there as they slap the $HALO back on it in RYTM.
0 · Reply
Sean29md
Sean29md Jul. 25 at 10:53 PM
$HALO https://www.tipranks.com/news/company-announcements/halozymes-promising-cancer-study-a-potential-game-changer-in-oncology
1 · Reply
Halo202
Halo202 Jul. 24 at 12:33 AM
$HALO $60 tomorrow
0 · Reply
Sean29md
Sean29md Jul. 23 at 4:21 PM
$HALO https://www.prnewswire.com/news-releases/european-commission-approved-darzalex-faspro-for-adult-patients-with-smouldering-multiple-myeloma-302512103.html
0 · Reply
Sean29md
Sean29md Jul. 18 at 10:56 PM
$HALO hey Halozyme’s directors and executives, why don’t you learn from your peer at Crisper: “CRISPR Therapeutics (CRSP) Surges after Director Buys over $51M Worth of Shares” https://www.tipranks.com/news/crispr-therapeutics-crsp-surges-after-director-buys-over-51m-worth-of-shares#google_vignette
0 · Reply
DTEXDoug
DTEXDoug Jul. 18 at 6:57 PM
$HALO Massive gap that will fill!
0 · Reply
Doozio
Doozio Jul. 17 at 2:45 AM
A $LEGN of them with that $HALO slapped back on. Whuts gonna stop 🐒🍌🧠⏰♾️?
0 · Reply
Sean29md
Sean29md Jul. 16 at 11:02 PM
$HALO https://www.ainvest.com/news/halozyme-therapeutics-20-cagr-growth-story-powered-enhanze-litigation-upside-undervalued-potential-2507/
0 · Reply
Sean29md
Sean29md Jul. 16 at 6:29 PM
$HALO JP Morgan raised it price target to $60. https://www.benzinga.com/quote/halo/analyst-ratings
0 · Reply
Biotech102
Biotech102 Jul. 16 at 1:40 PM
$HALO anyone see the jnj numbers on darzalex, should be a leading indicator for HALO earnings…
0 · Reply
Zeeb84
Zeeb84 Jul. 11 at 4:45 PM
$GME $SBET $HALO $SGN : $SGN is a 3.6M public float with no shares available (I do not believe) to short. It can fly with buy at the ask pressure. This could easily be a parabolic mover if everyone buys as we go into the weekend… I’d love to see the panic set in on the shorts for the last two hours of the day and a mad sell off to save their asses. Spread the word
0 · Reply
JR603
JR603 Jul. 10 at 1:09 PM
$HALO QUESTION TO CHART READERS - there seems to be a regular pattern of major trades occurring right before the market closes. Most days of late it seems to be driving the price higher. Any theories as to why? Thanks.
0 · Reply
Sean29md
Sean29md Jul. 9 at 1:04 PM
$HALO As predicted, the genius analyst who downgraded halozyme due to CMS price negotiations is too slow to recognize that the Orphan Cures Act included in the BBB and signed into law last week prevents CMS price negotiations for Faspro and other Enhanze partnered drugs. But the markets clearly picked up this nugget. By the time this analyst reverses his call, halo will be trading well into $60’s.
0 · Reply
Estimize
Estimize Jul. 7 at 7:02 PM
Wall St is expecting 1.21 EPS for $HALO Q2 [Reporting 08/12 AMC] http://www.estimize.com/intro/halo?chart=historical&metric_name=eps&utm_co
0 · Reply
Sean29md
Sean29md Jul. 3 at 7:18 PM
$HALO The exclusion of Orphan Drugs from CMS price negotiations got approved by the House today (included in the Big Beautiful Bill) and will be signed into law by Trump tomorrow. Darzlex, Opdivo and most Halozyme Enhanze partnered products already have the Orphan Designation. Halozyme's share price decline in May form high $60's to low $50's was due to an analyst (Leerink Partners) downgrade based on his concern with CMS price negotiations affecting halozyme's earnings from Darzelx/Faspro. Since this threat is removed, expect share price recovering in short order. I wouldn't hold your breath on the analyst reversing his call. They are typically slow. https://www.mmm-online.com/news/one-big-beautiful-bill-passes-heres-what-pharma-marketers-need-to-know/
2 · Reply
Sean29md
Sean29md Jul. 2 at 4:44 PM
$ARBK $HALO
0 · Reply